SEARCH

SEARCH BY CITATION

References

  • 1
    Currey HLF: Comparison of azathioprine, cyclophosphamide and gold in treatment of RA. Br Med J 3: 763766, 1974
  • 2
    Cooperating Clinics Committee of the American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 283: 883889, 1970
  • 3
    Ianuzzi L, Dawson N, Zein N, Kushman I: Does drug therapy slow radiographic progression in rheumatoid arthritis? N Engl J Med 309: 10231028, 1983
  • 4
    Csuka M, Carrera G, McCarty D: Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a follow-up study. JAMA 255: 23152319, 1986
  • 5
    Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 116: 488498, 1992
  • 6
    Fauci AS, Katz P, Haynes B, Wolff S: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 301: 235240, 1979
  • 7
    Fauci AS, Haynes B, Katz P, Wolff S: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 7685, 1983
  • 8
    Pedersen-Bjergaard J, Ersoboll J, Hansen V, Sorensen BL, Christofferson K, Hou-Jensen K, Nissen NI, Knudson JB, Hansen MM: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318: 10281032, 1988
  • 9
    Tucker M, Meadows A, Boice J: Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78: 455464, 1987
  • 10
    Parsons J, Strong J, Fosdick W: The causes of death in patients with rheumatoid arthritis treatment with cytotoxic agents (abstract). J Rheumatol 1 (Suppl): 75, 1974
  • 11
    Farber SJ, Sheon RP, Kirsner AB, Finkel RI: Incidence of malignant disease in patients receiving cytotoxic therapy for rheumatoid arthritis (abstract). Arthritis Rheum 22 (suppl 6): 608, 1979
  • 12
    Boyle DJ, Day JF, Kassan SS, Thomas MR, Robinson WA, Steigerwald JC: Incidence of malignancy 10 years following cyclophosphamide use for rheumatoid arthritis (abstract). Arthritis Rheum 27 (Suppl 4): S71, 1981
  • 13
    Baltus J, Boersma W, Hartman A, Vandenbroucke J: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 42: 368373, 1983
  • 14
    Baker G, Kahl L, Zee B, Stolzer B, Agarwal A, Medsger T: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Am J Med 83: 19, 1987
  • 15
    Steinbrocker O, Traeger C, Batterman R: Therapeutic criteria in rheumatoid arthritis. JAMA 140: 659652, 1949
  • 16
    Gridley G, McLaughlin J, Ekbom E, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumen JF Jr.: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85: 307311, 1993
  • 17
    Isomäki H, Hakulinen T, Joutsenlahti U: Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691696, 1978
  • 18
    Prior P, Symmons D, Hawkins C, Scott D, Brown R: Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43: 128131, 1984
  • 19
    Silman A, Petrie J, Hazleman B, Evans S: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow up study. Ann Rheum Dis 47: 988992, 1988
  • 20
    Porter D, Madhok R, Capell H: Non-Hodgkin's lymphoma in rheumatoid arthritis. Ann Rheum Dis 50: 275276, 1991
  • 21
    Katusic S, Beard M, Kurland L, Weis J, Bergstralh E: Occurrence of malignant neoplasms in the Rochester, Minnesota, rheumatoid arthritis cohort. Am J Med 78: 5055, 1985
  • 22
    Laakso M, Mutru O, Isomäki Koota K: Cancer mortality in patients with rheumatoid arthritis. J Rheumatol 13: 522526, 1986
  • 23
    Fries J, Bloch D, Spitz P, Mitchell D: Cancer in rheumatoid arthritis: a prospective long-term study of mortality. Am J Med 78: 5659, 1985
  • 24
    Lewis P, Hazleman B, Hanka B, Roberts S: Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 39: 457461, 1980
  • 25
    Gridley G, Klipple J, Hoover R, Fraumeni JJF: Incidence of cancer among men with the Felty Syndrome. Ann Intern Med 120: 3539, 1994
  • 26
    Plotz P, Klippel J, Decker J, Grauman D, Wolff B, Brown BC, Rutt G: Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 91: 221223, 1979
  • 27
    Stillwell T, Benson R: Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer 61: 451457, 1988
  • 28
    Stillwell TJ, Benson RC Jr, De Remee RA, McDonald TJ, Weiland LH: Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 31: 465470, 1988
  • 29
    ReisL, MillerB, HankeyB, KosaryC, HarrasA, EdwardsB, eds: SEER Cancer Statistics Review, 1973–1991: Tables and Graphs. NIH publication no. 94–2789. Bethesda, MD: National Cancer Institute, 1994
  • 30
    Tolchin SF, Winkelstein A, Rodnan GP, Pan SF, Nankin HR: Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum 17: 375382, 1974
  • 31
    Sessons S, Kovarsky J: Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus. Clin Exp Rheumatol 2: 247251, 1984
  • 32
    Grananger W, Benke-Studnicka A, Smolen J: Side effects of high dose bolus cyclophosphamide therapy of systemic lupus erythematosus (abstract). ILAR Conference of Rheumatology, Rio de Janeiro, Brazil, September, 1989
  • 33
    Gibbons RB, Westerman E: Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31: 15521554, 1988
  • 34
    Arnold MH, Janssen B, Schrieber L, Brooks PM: Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis. Arthritis Rheum 32: 933934, 1989